(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 June 2014 (19.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/091316 A2

(51) International Patent Classification:
C07K 14/435 (2006.01)

(21) International Application Number:
PCT/IB2013/003191

(22) International Filing Date:
10 December 2013 (10.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/735,823 11 December 2012 (11.12.2012) US

(71) Applicant: **MEDIMMUNE LIMITED** [—/GB]; Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(72) Inventors: **AGORAM, Balaji**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **ANTONSSON, Madeleine**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **BEDNAREK, Maria**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **BURMEISTER, Nicole**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **BENTHEM, Lambertus**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **FAIRMAN, David**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **FRITSCH-FREDIN, Maria**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **JACKSON, Ronald**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **LOFMARK, Rasmus, Jansson**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **METCALFE, Jacqueline**; C/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(74) Agents: **TTOFI, Evangelia** et al.; MedImmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY




FIG. 1

(57) Abstract: This disclosure provides GLP-1 /glue agon agonist peptides for the treatment of metabolic diseases, *e.g.*, obesity.

WO 2014/091316 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*